Phase II Trial of Dose-Dense R-CHOP Followed by Risk-Adapted Consolidation with Either ICE or ICE and ASCT, Based upon the Results of Biopsy Confirmed Abnormal Interim Restaging PET Scan, Improves Outcome in Patients with Advanced Stage DLBCL.

In pts 80%, p=0.0006 and MUM1 positivity: p=0.034. In conclusion, this is the first study that attempts to risk-adapt therapy for DLBCL based upon tissue confirmation of an abnormal interim restaging PET scan. In fact, in this study, treatment decisions based on PET findings alone would have over-treated (stratification to HDT/ASCT) 27 of the 87 patients (31%) enrolled on protocol. Our dose-dense approach employing induction with R-CHOP-14 followed by ICE consolidation may overcome the poor risk features of the standard prognostic models used for DLBCL. This approach results in an excellent EFS and may obviate the need for an upfront ASCT in nearly all pts.